Market Cap 145.93B
Revenue (ttm) 25.12B
Net Income (ttm) 3.25B
EPS (ttm) N/A
PE Ratio 28.23
Forward PE 25.79
Profit Margin 12.92%
Debt to Equity Ratio 0.71
Volume 1,013,600
Avg Vol 1,939,484
Day's Range N/A - N/A
Shares Out 382.69M
Stochastic %K 83%
Beta 0.87
Analysts Strong Sell
Price Target $429.96

Company Profile

Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the t...

Industry: Medical Devices
Sector: Healthcare
Phone: (269) 385-2600
Fax: (269) 385-1062
Address:
1941 Stryker Way, Portage, United States
SparkyReturns
SparkyReturns Feb. 25 at 7:59 PM
$ICU I wonder how many investors will actually take 30 seconds to review this and fully understand what it means? This will be a Billion dollar company in no time. Just watch. $SYK $MCK $MDT $BAYRY
2 · Reply
ZacksResearch
ZacksResearch Feb. 25 at 5:30 PM
$SYK rolls out a next-gen ankle fixation system — and this one could quietly expand its footprint 👀 Synchfix EVT is designed to streamline surgery and broaden reach into adolescent trauma care, adding another growth lever to the portfolio. Is this launch a meaningful catalyst for the medtech leader? Get the full breakdown 👉 https://www.zacks.com/stock/news/2875273/stryker-launches-synchfix-evt-for-flexible-syndesmotic-fixation?cid=sm-stocktwits-2-2875273-teaser-35179&ADID=SYND_STOCKTWITS_TWEET_2_2875273_TEASER_35179
0 · Reply
ZacksResearch
ZacksResearch Feb. 25 at 4:30 PM
$SYK unveils Synchfix EVT — significant addition to ankle trauma care? 🦶 🌟 First flexible syndesmotic device approved for adolescents 🔧 Innovative all-in-one design boosts surgical efficiency 📉 Share dip of 0.9% following the announcement Learn more about SYK’s growth strategy and market prospects. https://www.zacks.com/stock/news/2875273/stryker-launches-synchfix-evt-for-flexible-syndesmotic-fixation?cid=sm-stocktwits-2-2875273-body-35136&ADID=SYND_STOCKTWITS_TWEET_2_2875273_BODY_35136
0 · Reply
erevnon
erevnon Feb. 24 at 8:48 PM
UBS maintains Stryker $SYK at Neutral and raises the price target from $386 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Highbank
Highbank Feb. 24 at 12:58 AM
0 · Reply
TracyHuerta613
TracyHuerta613 Feb. 21 at 6:58 AM
$SYK Stryker supplies orthopedic and surgical devices. Growth driven by procedure volumes. Margins are strong and stable.
0 · Reply
Danniess
Danniess Feb. 17 at 2:53 PM
$SYK 3.23% week on 88 vol, I’m short, that’s a fake tape
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 17 at 12:52 AM
$SYK Share Price: $366.03 Contract Selected: Sep 18, 2026 $370 Calls Buy Zone: $22.61 – $27.93 Target Zone: $41.57 – $50.80 Potential Upside: 74% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Marcusjoback
Marcusjoback Feb. 13 at 1:32 AM
Intuitive Surgical has da Vinci for the soft tissue robotic-assisted surgery space while Stryker offers the Mako robotic platform for orthopedic procedures, so besides $MBOT there's really only Stereotaxis GenesisX in our space that uses external magnets primarily for arrhythmias and atrial fibrillation but requires a more costly permanent specialized operating room setup versus LIBERTY that aims to remove the high cost barriers as a remote, disposable and safer option that virtually eliminates exposure to radiation that can be used in more broader, diverse applications including neurovascular, cardiovascular, and peripheral vascular procedures. The Miami show lit the fuse! $ISRG & $SYK you are on the clock ✌️
1 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 7:00 PM
$SYK just expanded its trauma playbook — and this one matters. 🦴 The company launched the T2 Alpha Humerus Nailing System to enhance complex fracture care, aiming to boost procedural efficiency while strengthening its trauma portfolio. That’s smart portfolio depth in a high-need category. Is this launch a quiet growth driver? See the full impact here 👉 https://www.zacks.com/stock/news/2863461/stryker-launches-t2-alpha-humerus-nailing-system-for-fracture-care?cid=sm-stocktwits-2-2863461-teaser-33442&ADID=SYND_STOCKTWITS_TWEET_2_2863461_TEASER_33442
0 · Reply
Latest News on SYK
Stryker declares an $0.88 per share quarterly dividend

Feb 4, 2026, 8:00 AM EST - 21 days ago

Stryker declares an $0.88 per share quarterly dividend


Stryker Corporation (SYK) Q4 2025 Earnings Call Transcript

Jan 30, 2026, 12:32 AM EST - 27 days ago

Stryker Corporation (SYK) Q4 2025 Earnings Call Transcript


Stryker reports 2025 operating results and 2026 outlook

Jan 29, 2026, 4:05 PM EST - 27 days ago

Stryker reports 2025 operating results and 2026 outlook


Stryker Corporation (SYK) Analyst/Investor Day Transcript

Nov 19, 2025, 6:03 PM EST - 3 months ago

Stryker Corporation (SYK) Analyst/Investor Day Transcript


Why Stryker Stock May Be Headed For A Prolonged Slowdown

Nov 17, 2025, 7:48 AM EST - 3 months ago

Why Stryker Stock May Be Headed For A Prolonged Slowdown


Stryker: Strong Growth, But Valuation Is A Concern

Nov 4, 2025, 10:22 PM EST - 4 months ago

Stryker: Strong Growth, But Valuation Is A Concern


Stryker: Striking Again

Nov 3, 2025, 4:30 AM EST - 4 months ago

Stryker: Striking Again


Stryker Corporation (SYK) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:16 PM EDT - 4 months ago

Stryker Corporation (SYK) Q3 2025 Earnings Call Transcript


Stryker raises lower end of annual profit forecast

Oct 30, 2025, 7:04 PM EDT - 4 months ago

Stryker raises lower end of annual profit forecast


Stryker reports third quarter 2025 operating results

Oct 30, 2025, 4:05 PM EDT - 4 months ago

Stryker reports third quarter 2025 operating results


Stryker Launches Incompass Total Ankle System at AOFAS 2025

Sep 9, 2025, 7:20 AM EDT - 6 months ago

Stryker Launches Incompass Total Ankle System at AOFAS 2025


Stryker Q2: Record Mako Installation And High Utilization

Aug 19, 2025, 2:55 PM EDT - 6 months ago

Stryker Q2: Record Mako Installation And High Utilization


Stryker to host investor day

Aug 15, 2025, 8:00 AM EDT - 6 months ago

Stryker to host investor day


Stryker declares an $0.84 per share quarterly dividend

Aug 7, 2025, 8:00 AM EDT - 7 months ago

Stryker declares an $0.84 per share quarterly dividend


Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:59 PM EDT - 7 months ago

Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript


Stryker reports second quarter 2025 operating results

Jul 31, 2025, 4:05 PM EDT - 7 months ago

Stryker reports second quarter 2025 operating results


The Big 3: NXT, ANET, SYK

Jun 26, 2025, 1:01 PM EDT - 8 months ago

The Big 3: NXT, ANET, SYK

ANET NXT


Stryker receives FDA clearance for Incompass Total Ankle System

Jun 25, 2025, 8:15 AM EDT - 8 months ago

Stryker receives FDA clearance for Incompass Total Ankle System


The 3 Most Overvalued Stocks Top Managers Are Selling in 2025

Jun 3, 2025, 11:09 AM EDT - 9 months ago

The 3 Most Overvalued Stocks Top Managers Are Selling in 2025

MA NFLX


Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:28 PM EDT - 10 months ago

Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript


Stryker reports first quarter 2025 operating results

May 1, 2025, 4:05 PM EDT - 10 months ago

Stryker reports first quarter 2025 operating results


SparkyReturns
SparkyReturns Feb. 25 at 7:59 PM
$ICU I wonder how many investors will actually take 30 seconds to review this and fully understand what it means? This will be a Billion dollar company in no time. Just watch. $SYK $MCK $MDT $BAYRY
2 · Reply
ZacksResearch
ZacksResearch Feb. 25 at 5:30 PM
$SYK rolls out a next-gen ankle fixation system — and this one could quietly expand its footprint 👀 Synchfix EVT is designed to streamline surgery and broaden reach into adolescent trauma care, adding another growth lever to the portfolio. Is this launch a meaningful catalyst for the medtech leader? Get the full breakdown 👉 https://www.zacks.com/stock/news/2875273/stryker-launches-synchfix-evt-for-flexible-syndesmotic-fixation?cid=sm-stocktwits-2-2875273-teaser-35179&ADID=SYND_STOCKTWITS_TWEET_2_2875273_TEASER_35179
0 · Reply
ZacksResearch
ZacksResearch Feb. 25 at 4:30 PM
$SYK unveils Synchfix EVT — significant addition to ankle trauma care? 🦶 🌟 First flexible syndesmotic device approved for adolescents 🔧 Innovative all-in-one design boosts surgical efficiency 📉 Share dip of 0.9% following the announcement Learn more about SYK’s growth strategy and market prospects. https://www.zacks.com/stock/news/2875273/stryker-launches-synchfix-evt-for-flexible-syndesmotic-fixation?cid=sm-stocktwits-2-2875273-body-35136&ADID=SYND_STOCKTWITS_TWEET_2_2875273_BODY_35136
0 · Reply
erevnon
erevnon Feb. 24 at 8:48 PM
UBS maintains Stryker $SYK at Neutral and raises the price target from $386 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Highbank
Highbank Feb. 24 at 12:58 AM
0 · Reply
TracyHuerta613
TracyHuerta613 Feb. 21 at 6:58 AM
$SYK Stryker supplies orthopedic and surgical devices. Growth driven by procedure volumes. Margins are strong and stable.
0 · Reply
Danniess
Danniess Feb. 17 at 2:53 PM
$SYK 3.23% week on 88 vol, I’m short, that’s a fake tape
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 17 at 12:52 AM
$SYK Share Price: $366.03 Contract Selected: Sep 18, 2026 $370 Calls Buy Zone: $22.61 – $27.93 Target Zone: $41.57 – $50.80 Potential Upside: 74% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Marcusjoback
Marcusjoback Feb. 13 at 1:32 AM
Intuitive Surgical has da Vinci for the soft tissue robotic-assisted surgery space while Stryker offers the Mako robotic platform for orthopedic procedures, so besides $MBOT there's really only Stereotaxis GenesisX in our space that uses external magnets primarily for arrhythmias and atrial fibrillation but requires a more costly permanent specialized operating room setup versus LIBERTY that aims to remove the high cost barriers as a remote, disposable and safer option that virtually eliminates exposure to radiation that can be used in more broader, diverse applications including neurovascular, cardiovascular, and peripheral vascular procedures. The Miami show lit the fuse! $ISRG & $SYK you are on the clock ✌️
1 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 7:00 PM
$SYK just expanded its trauma playbook — and this one matters. 🦴 The company launched the T2 Alpha Humerus Nailing System to enhance complex fracture care, aiming to boost procedural efficiency while strengthening its trauma portfolio. That’s smart portfolio depth in a high-need category. Is this launch a quiet growth driver? See the full impact here 👉 https://www.zacks.com/stock/news/2863461/stryker-launches-t2-alpha-humerus-nailing-system-for-fracture-care?cid=sm-stocktwits-2-2863461-teaser-33442&ADID=SYND_STOCKTWITS_TWEET_2_2863461_TEASER_33442
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 6:00 PM
$SYK's new launch: A game-changer in orthopedic trauma? 💡 The T2 Alpha Humerus Nailing System promises increased procedural flexibility and enhanced fixation stability for complex humeral fractures, potentially supporting revenue growth and competitive differentiation in the orthopedic trauma market. Discover the full potential of SYK's innovation here 👉 https://www.zacks.com/stock/news/2863461/stryker-launches-t2-alpha-humerus-nailing-system-for-fracture-care?cid=sm-stocktwits-2-2863461-body-33424&ADID=SYND_STOCKTWITS_TWEET_2_2863461_BODY_33424
0 · Reply
Highbank
Highbank Feb. 12 at 3:04 PM
$SYK Nice continuation.
0 · Reply
TechTraderGrok
TechTraderGrok Feb. 11 at 8:58 PM
Bought $SYK at $363.42. From Grok: "Re-enter LONG soon after exit as MACD bullish crossover and price above EMAs signal renewed momentum overriding prior bearish signals, supported by strong 2025 results and decreased short interest, despite ongoing insider sale concerns. (148 chars)" https://www.techtrader.ai/grokwall/?post=16411&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Jstoefen
Jstoefen Feb. 10 at 3:41 AM
$SYK added today
0 · Reply
richard74
richard74 Feb. 8 at 2:48 PM
$SYK good set up. $400
0 · Reply
Danny696
Danny696 Feb. 7 at 6:30 PM
$SYK Short this POS and thank me later.
1 · Reply
richard74
richard74 Feb. 6 at 5:37 PM
$SYK adding here
0 · Reply
TitanCapital
TitanCapital Feb. 4 at 11:28 AM
$SYK is a high-quality orthopedics and medtech player; pricing environment and new product cycles are favorable.
0 · Reply
richard74
richard74 Feb. 3 at 4:36 PM
$LULU $MSFT $SYK. Adding here.
2 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 7:22 PM
$SYK beats Q4 earnings estimates — what's fueling the growth? 🚀 💰 Adjusted EPS of $4.47, topping estimates by 1.6% and rising 11.5% year over year 📈 Revenue surged to $7.17B, up 11.4% year over year with strong organic growth of 11% 💼 Strategic divestments & robust Mako platform adoption driving future prospects Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2826281/syk-stock-gains-as-q4-earnings-sales-beat-on-strong-mako-adoption?cid=sm-stocktwits-2-2826281-body-31316&ADID=SYND_STOCKTWITS_TWEET_2_2826281_BODY_31316
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 6:22 PM
$SYK popping after Q4 — this is what strong execution looks like. 🚀 Fourth-quarter EPS and sales beat estimates, driven by double-digit organic growth and strong adoption of the Mako platform. See what’s powering the move and what it could mean next 👉 https://www.zacks.com/stock/news/2826281/syk-stock-gains-as-q4-earnings-sales-beat-on-strong-mako-adoption?cid=sm-stocktwits-2-2826281-teaser-31315&ADID=SYND_STOCKTWITS_TWEET_2_2826281_TEASER_31315
0 · Reply
erevnon
erevnon Jan. 30 at 10:54 AM
BTIG maintains Stryker $SYK at Buy and raises the price target from $410 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply